Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2024; 16(6): 2862-2864
Published online Jun 15, 2024. doi: 10.4251/wjgo.v16.i6.2862
New perspectives in prognostication of hepatocellular carcinoma: The role and clinical implications of transient receptor potential family genes
Shi-Hao Guan, Wen-Jing Hu, Xin-Yu Wang, Yue-Xia Gu, De-Hua Zhou
Shi-Hao Guan, Department of Plastic Surgery, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai 201700, China
Wen-Jing Hu, Yue-Xia Gu, Department of Nursing, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China
Xin-Yu Wang, Department of Thyroid, Breast and Vascular Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China
De-Hua Zhou, Department of Gastrointestinal Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China
Co-first authors: Shi-Hao Guan and Wen-Jing Hu.
Author contributions: Guan SH and Hu WJ jointly contributed as co-first authors in the analysis and manuscript writing; Wang XY and Gu YX provided critical revisions of the manuscript; Zhou DH conceptualized and supervised the article’s development, also contributing to its critical revision; and all authors have read and endorsed the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: De-Hua Zhou, MM, Surgeon, Department of Gastrointestinal Surgery, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, No. 1279 Sanmen Road, Hongkou District, Shanghai 200434, China. deachzdh@163.com
Received: January 17, 2024
Revised: May 2, 2024
Accepted: May 11, 2024
Published online: June 15, 2024
Processing time: 149 Days and 12.4 Hours
Abstract

The study titled “Transient receptor potential-related risk model predicts prognosis of hepatocellular carcinoma patients” is a significant contribution to hepatocellular carcinoma (HCC) research, highlighting the role of transient receptor potential (TRP) family genes in the disease’s progression and prognosis. Utilizing data from The Cancer Genome Atlas database, it establishes a new risk assessment model, emphasizing the interaction of TRP genes with tumor proliferation pathways, key metabolic reactions like retinol metabolism, and the tumor immune microenvironment. Notably, the overexpression of the TRPC1 gene in HCC correlates with poorer patient survival outcomes, suggesting its potential as a prognostic biomarker and a target for personalized therapy, particularly in strategies combining immunotherapy and anti-TRP agents.

Keywords: Hepatocellular carcinoma; Transient receptor potential channels; TRPC1 gene; Tumor immune microenvironment; Cancer prognosis; Bioinformatics in cancer research

Core Tip: This pivotal study unveils a novel risk assessment model based on transient receptor potential (TRP) family genes, offering significant advancements in the prognostication and personalized treatment of hepatocellular carcinoma (HCC). It highlights the crucial role of TRPC1 gene expression as a prognostic marker linked to patient survival and disease progression, potentially reshaping HCC therapeutic strategies. The findings underscore the importance of TRP genes in cancer biology, particularly their integration with tumor immune responses, paving the way for innovative treatments that combine immunotherapy with targeted TRP gene inhibition.